Olema PharmaceuticalsOLMA
About: Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Employees: 88
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
905% more call options, than puts
Call options by funds: $2.87M | Put options by funds: $286K
12% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 42
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
5% more capital invested
Capital invested by funds: $665M [Q2] → $700M (+$35.5M) [Q3]
2% more funds holding
Funds holding: 128 [Q2] → 130 (+2) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
7.43% less ownership
Funds ownership: 109.86% [Q2] → 102.43% (-7.43%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for OLMA.
Financial journalist opinion
Based on 5 articles about OLMA published over the past 30 days